ATE488586T1 - In vitro peptid-expressionsbank - Google Patents

In vitro peptid-expressionsbank

Info

Publication number
ATE488586T1
ATE488586T1 AT03793896T AT03793896T ATE488586T1 AT E488586 T1 ATE488586 T1 AT E488586T1 AT 03793896 T AT03793896 T AT 03793896T AT 03793896 T AT03793896 T AT 03793896T AT E488586 T1 ATE488586 T1 AT E488586T1
Authority
AT
Austria
Prior art keywords
peptide expression
vitro peptide
library
expression bank
making
Prior art date
Application number
AT03793896T
Other languages
English (en)
Inventor
Duncan Mcgregor
Richard Odegrip
Kevin Fitzgerald
Rosemarie Hederer
Bill Eldridge
Chris Ullman
Philip Kuhlman
David Coomber
Original Assignee
Isogenica Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0220759A external-priority patent/GB0220759D0/en
Priority claimed from GB0304521A external-priority patent/GB0304521D0/en
Priority claimed from GB0304657A external-priority patent/GB0304657D0/en
Application filed by Isogenica Ltd filed Critical Isogenica Ltd
Application granted granted Critical
Publication of ATE488586T1 publication Critical patent/ATE488586T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1075—Isolating an individual clone by screening libraries by coupling phenotype to genotype, not provided for in other groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT03793896T 2002-09-06 2003-09-05 In vitro peptid-expressionsbank ATE488586T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0220759A GB0220759D0 (en) 2002-09-06 2002-09-06 Display library
GB0304521A GB0304521D0 (en) 2003-02-27 2003-02-27 Display library
GB0304657A GB0304657D0 (en) 2003-02-28 2003-02-28 Display library
PCT/GB2003/003860 WO2004022746A1 (en) 2002-09-06 2003-09-05 In vitro peptide expression libraray

Publications (1)

Publication Number Publication Date
ATE488586T1 true ATE488586T1 (de) 2010-12-15

Family

ID=31982028

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03793896T ATE488586T1 (de) 2002-09-06 2003-09-05 In vitro peptid-expressionsbank

Country Status (14)

Country Link
US (2) US7842476B2 (de)
EP (2) EP1534830B1 (de)
JP (1) JP4664677B2 (de)
KR (1) KR101051245B1 (de)
CN (1) CN100351375C (de)
AT (1) ATE488586T1 (de)
AU (1) AU2003260786B2 (de)
CA (1) CA2497496C (de)
DE (1) DE60335000D1 (de)
DK (1) DK1534830T3 (de)
IL (1) IL166903A (de)
NO (1) NO332949B1 (de)
PT (1) PT1534830E (de)
WO (1) WO2004022746A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0418651D0 (en) 2004-08-20 2004-09-22 Medical Res Council Method
GB0505420D0 (en) * 2005-03-16 2005-04-20 Isogenica Ltd Stable ligand selection method
GB0515115D0 (en) * 2005-07-22 2005-08-31 Isogenica Ltd Peptide characterisation
GB0806562D0 (en) 2008-04-10 2008-05-14 Fermentas Uab Production of nucleic acid
EP2316030B1 (de) 2008-07-25 2019-08-21 Wagner, Richard W. Proteinscreeningverfahren
ES2705714T3 (es) 2008-10-31 2019-03-26 Janssen Biotech Inc Métodos y usos de dominio de Fibronectina tipo III basado en estructuras de composiciones
EP2403864B1 (de) 2009-02-27 2015-08-12 Atyr Pharma, Inc. Polypeptidstrukturmotive im zusammenhang mit zellsignalisierungsaktivität
GB201000352D0 (en) 2010-01-11 2010-02-24 Isogenica Ltd Antimicrobial peptides
CA2797093C (en) 2010-04-26 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
EP2563381B1 (de) 2010-04-27 2017-08-09 aTyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von isoleucyl-trna-synthetasen
AU2011248521B2 (en) 2010-04-27 2017-03-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl tRNA synthetases
CN103097524B (zh) 2010-04-28 2016-08-03 Atyr医药公司 与丙氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
EP2563383B1 (de) 2010-04-29 2017-03-01 Atyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von valyl-trna-synthetasen
CA2797374C (en) 2010-04-29 2021-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
US8569227B2 (en) 2010-04-30 2013-10-29 Janssen Biotech, Inc. Stabilized fibronectin domain compositions, methods and uses
EP2566516B1 (de) 2010-05-03 2019-07-03 aTyr Pharma, Inc. Innovative entdeckung von therapeutischen und diagnostischen mitteln sowie antikörperzusammensetzungen im zusammenhang mit proteinfragmenten von seryl-trna-synthetasen
AU2011248227B2 (en) 2010-05-03 2016-12-01 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
CN103096925A (zh) 2010-05-03 2013-05-08 Atyr医药公司 与精氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
ES2668207T3 (es) 2010-05-03 2018-05-17 Atyr Pharma, Inc. Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de metionil-ARNt sintetasas
JP6008844B2 (ja) 2010-05-04 2016-10-19 エータイアー ファーマ， インコーポレイテッド ｐ３８ＭＵＬＴＩ−ｔＲＮＡ合成酵素複合体のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
CN103096909A (zh) 2010-05-04 2013-05-08 Atyr医药公司 与谷氨酰-脯氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
EP2568996B1 (de) 2010-05-14 2017-10-04 aTyr Pharma, Inc. Therapeutische, diagnostische und antikörperhaltige zusammensetzungen im zusammenhang mit proteinfragmenten von phenylalanyl-beta-trna-synthetasen
US9034598B2 (en) 2010-05-17 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
CN103096913B (zh) 2010-05-27 2017-07-18 Atyr 医药公司 与谷氨酰胺酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CA2800281C (en) 2010-06-01 2021-01-12 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
US8999321B2 (en) 2010-07-12 2015-04-07 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
KR20130102534A (ko) 2010-07-12 2013-09-17 에이티와이알 파마, 인코포레이티드 히스티딜­trna 합성효소의 단백질 단편에 관련된 치료적, 진단적, 및 항체 조성물의 혁신적 발견
KR20180059575A (ko) 2010-07-12 2018-06-04 에이티와이알 파마, 인코포레이티드 아스파르틸­trna 합성효소의 단백질 단편에 관련된 치료적, 진단적, 및 항체 조성물의 혁신적 발견
AU2011289831C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
GB201013284D0 (en) 2010-08-06 2010-09-22 Isogenica Ltd Scaffold peptides
CN103108650A (zh) 2010-08-25 2013-05-15 Atyr医药公司 与酪氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN103118696B (zh) 2010-10-06 2020-02-14 Atyr 医药公司 与色氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物
JP5920835B2 (ja) 2010-12-01 2016-05-18 田辺三菱製薬株式会社 無細胞翻訳系でＦａｂを提示しうるポリヌクレオチド構築物ならびにそれを用いたＦａｂの製造方法およびスクリーニング方法
US9714419B2 (en) 2011-08-09 2017-07-25 Atyr Pharma, Inc. PEGylated tyrosyl-tRNA synthetase polypeptides
JP6440496B2 (ja) 2011-09-27 2018-12-19 ヤンセン バイオテツク，インコーポレーテツド 選択的結合表面を有するフィブロネクチンｉｉｉ型反復ベースのタンパク質スカフォールド
US20130090266A1 (en) 2011-10-11 2013-04-11 Biolauncher Ltd. Methods and systems for optimization of peptide screening
US20130090247A1 (en) 2011-10-11 2013-04-11 Biolauncher Ltd. Methods and systems for identification of binding pharmacophores
US20130090265A1 (en) 2011-10-11 2013-04-11 Biolauncher Ltd. Systems and methods for generation of context-specific, molecular field-based amino acid substitution matrices
WO2013086216A1 (en) 2011-12-06 2013-06-13 Atyr Pharma, Inc. Improved aspartyl-trna synthetases
WO2013086228A1 (en) 2011-12-06 2013-06-13 Atyr Pharma, Inc. Pegylated aspartyl-trna synthetase polypeptides
CA2858613A1 (en) 2011-12-29 2013-08-08 Atyr Pharma, Inc. Aspartyl-trna synthetase-fc conjugates
GB2500243A (en) * 2012-03-15 2013-09-18 Isogenica Ltd Identifying members of immobilised peptide libraries comprising protein-DNA complexes
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
MX361088B (es) 2012-11-21 2018-11-26 Janssen Biotech Inc Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos.
ES2708565T3 (es) 2013-03-15 2019-04-10 Atyr Pharma Inc Conjugados de Fc-histidil-ARNt sintetasa
BR112016008125B1 (pt) 2013-10-14 2023-11-21 Janssen Biotech, Inc. Domínio proteico isolado de fibronectina tipo iii modificado com cisteína, seu método de produção e método para produzir uma molécula isolada de de fibronectina tipo iii biespecífica modificada com cisteína
CN107614703A (zh) 2015-02-27 2018-01-19 香港大学 Dna展示及其方法
RS61907B1 (sr) 2015-04-06 2021-06-30 Subdomain Llc Polipeptidi koji sadrže de novo vezujući domen i njihova primena
US10844111B2 (en) 2015-05-06 2020-11-24 Janssen Biotech, Inc. Prostate specific membrane antigen binding fibronectin type III domains
SG11201810687SA (en) 2016-06-03 2018-12-28 Janssen Biotech Inc Serum albumin-binding fibronectin type iii domains
MA45412A (fr) 2016-06-21 2021-05-26 Janssen Biotech Inc Molécules de liaison au domaine de fibronectine de type iii modifiées par la cystéine
MA46236A (fr) 2016-09-14 2019-07-24 Janssen Biotech Inc Récepteurs antigéniques chimériques comprenant des domaines de la fibronectine de type iii spécifiques du bcma, et utilisations correspondantes
CN110225770B (zh) 2016-12-14 2022-04-26 杨森生物科技公司 结合cd8a的纤连蛋白iii型结构域
EP3554561B1 (de) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137-bindende fibronectin-typ-iii-domänen
EP3554535A4 (de) 2016-12-14 2020-10-21 Janssen Biotech, Inc. Pd-l1-bindende fibronectin-typ iii-domänen
EP3600394A4 (de) 2017-03-22 2021-04-14 Research Corporation Technologies, Inc. Manipulierte stabile ch2-polypeptide
CA3060514A1 (en) 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
JP7250766B2 (ja) 2017-08-25 2023-04-03 ヤンセン バイオテツク，インコーポレーテツド ＦＣγＲＩＩ結合フィブロネクチンＩＩＩ型ドメイン、それらのコンジュゲート、及びそれらを含む多重特異性分子
CN119119240A (zh) 2019-10-14 2024-12-13 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
WO2021076543A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Epcam binding fibronectin type iii domains
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
CN115175691B (zh) 2019-12-18 2026-02-10 Aro生物疗法公司 结合血清白蛋白的纤连蛋白iii型结构域及其应用
EP4323008A4 (de) 2021-04-14 2026-02-25 Aro Biotherapeutics Company Fn3-domänen-sirna-konjugate und verwendungen davon
CA3214552A1 (en) 2021-04-14 2022-10-20 Russell C. Addis Cd71 binding fibronectin type iii domains
WO2026073047A1 (en) 2024-09-27 2026-04-02 Applied Biomedical Science Institute Methods of screening and expressing cis-display libraries of disulfide-rich polypeptides

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU638762B2 (en) 1989-10-05 1993-07-08 Optein Inc Cell-free synthesis and isolation of novel genes and polypeptides
DK0593618T3 (da) * 1991-06-27 1998-11-23 Genelabs Tech Inc Screeningsassay til påvisning af DNA-bindende molekyler
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
GB9703369D0 (en) * 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
WO1998054312A1 (en) 1997-05-28 1998-12-03 Babraham Institute Ribosome complexes as selection particles for in vitro display and evolution of proteins
ES2230701T3 (es) 1997-07-07 2005-05-01 Medical Research Council Procedimiento de seleccion in vitro.
GB9718455D0 (en) * 1997-09-02 1997-11-05 Mcgregor Duncan P Chimeric binding peptide library screening method
GB9900298D0 (en) 1999-01-07 1999-02-24 Medical Res Council Optical sorting method
WO2000060070A1 (en) 1999-04-01 2000-10-12 Innogenetics N.V. A polypeptide structure for use as a scaffold
EP1350846A4 (de) 2000-12-07 2005-01-26 Univ Keio C-terminales modifiziertes protein und verfahren zu seiner herstellung, bei der herstellung von c-terminalem modifiziertem protein zu verwendendes modifikationsmittel und translationsvorlage und verfahren zum nachweis von proteinwechselwirkung unter verwendung des c-terminalen modifizierten proteins
JP4963142B2 (ja) 2000-12-14 2012-06-27 学校法人慶應義塾 遺伝子型と表現型の対応付け分子とその構成要素、および対応付け分子の製造方法と利用方法
WO2003014734A1 (fr) 2001-08-07 2003-02-20 Keio University Procede de detection d'une interaction entre une substance et une proteine, procede d'analyse de la proteine interagissant avec la substance et procede de formation d'un complexe contenant la substance et la proteine interagissant avec cette substance
US20060156511A1 (en) * 2005-01-19 2006-07-20 Li Yuan J Caster

Also Published As

Publication number Publication date
JP2005537795A (ja) 2005-12-15
NO332949B1 (no) 2013-02-04
EP1534830B1 (de) 2010-11-17
CN1681924A (zh) 2005-10-12
CN100351375C (zh) 2007-11-28
CA2497496A1 (en) 2004-03-18
AU2003260786A1 (en) 2004-03-29
US20060035232A1 (en) 2006-02-16
IL166903A (en) 2012-06-28
HK1072957A1 (en) 2005-09-16
KR20050057216A (ko) 2005-06-16
DE60335000D1 (de) 2010-12-30
PT1534830E (pt) 2011-01-31
US7842476B2 (en) 2010-11-30
EP2385118A1 (de) 2011-11-09
WO2004022746A1 (en) 2004-03-18
US8679781B2 (en) 2014-03-25
DK1534830T3 (da) 2011-02-14
AU2003260786B2 (en) 2008-03-13
NO20051685L (no) 2005-06-06
EP1534830A1 (de) 2005-06-01
KR101051245B1 (ko) 2011-07-21
US20120149591A1 (en) 2012-06-14
JP4664677B2 (ja) 2011-04-06
CA2497496C (en) 2012-05-15

Similar Documents

Publication Publication Date Title
ATE488586T1 (de) In vitro peptid-expressionsbank
GEP20094629B (en) Nogo receptor binding protein
WO2002040683A3 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2002046407A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002046406A3 (en) Human transporter proteins, nucleic acid molecules encoding them,and uses thereof
WO2002022678A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2001081412A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding the same, and uses thereof
WO2002072831A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002077190A8 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
WO2002024910A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding them, and uses thereof
WO2002057310A3 (en) Human transporter proteins, nucleic acid molecules encoding them, and uses thereof
WO2003074675A3 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
WO2002033086A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002020757A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002046217A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002024748A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002081654A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2003070882A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and used thereof
WO2001088136A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2001090360A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002066642A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002048366A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002048365A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002048364A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002053740A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1534830

Country of ref document: EP